Teva reports positive Phase 2a topline celiac disease results
Teva said its Phase 2a study in celiac disease for its anti-IL-15 antibody delivered positive topline results, further validating its pipeline-in-a-product potential.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.